S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01

Soleno Therapeutics Stock Forecast, Price & News

+0.00 (+0.96%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
196,700 shs
Average Volume
241,450 shs
Market Capitalization
$33.52 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SLNO News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Soleno Therapeutics logo

About Soleno Therapeutics

Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The firm focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.


See More Headlines

Industry, Sector and Symbol

Electromedical equipment
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$0.57 per share


Net Income
$-24.64 million
Pretax Margin




Free Float
Market Cap
$33.52 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.08 out of 5 stars

Medical Sector

536th out of 1,405 stocks

Electromedical Equipment Industry

12th out of 29 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -

Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions

Is Soleno Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Soleno Therapeutics stock.
View analyst ratings for Soleno Therapeutics
or view top-rated stocks.

How has Soleno Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Soleno Therapeutics' stock was trading at $2.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SLNO stock has decreased by 83.3% and is now trading at $0.42.
View which stocks have been most impacted by COVID-19

Are investors shorting Soleno Therapeutics?

Soleno Therapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 721,000 shares, an increase of 18.3% from the December 15th total of 609,500 shares. Based on an average trading volume of 256,700 shares, the days-to-cover ratio is currently 2.8 days. Currently, 1.3% of the shares of the company are short sold.
View Soleno Therapeutics' Short Interest

When is Soleno Therapeutics' next earnings date?

Soleno Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 2nd 2022.
View our earnings forecast for Soleno Therapeutics

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.10) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.11) by $0.01.
View Soleno Therapeutics' earnings history

When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?

Soleno Therapeutics's stock reverse split before market open on Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for SLNO?

1 brokers have issued 12-month price objectives for Soleno Therapeutics' shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate Soleno Therapeutics' stock price to reach $8.00 in the next year. This suggests a possible upside of 1,804.8% from the stock's current price.
View analysts' price targets for Soleno Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Soleno Therapeutics' key executives?

Soleno Therapeutics' management team includes the following people:
  • Anish Bhatnagar, President, Chief Executive Officer & Director
  • James H. Mackaness, Chief Financial Officer (LinkedIn Profile)
  • Kristen Yen, Vice President-Clinical Operations
  • Harish Ravivarapu, Vice President-Technical Operations
  • Patricia C. Hirano, Head-Regulatory Affairs & Quality

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD).

What is Soleno Therapeutics' stock symbol?

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

How do I buy shares of Soleno Therapeutics?

Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Soleno Therapeutics' stock price today?

One share of SLNO stock can currently be purchased for approximately $0.42.

How much money does Soleno Therapeutics make?

Soleno Therapeutics has a market capitalization of $33.52 million. The company earns $-24.64 million in net income (profit) each year or ($0.39) on an earnings per share basis.

How many employees does Soleno Therapeutics have?

Soleno Therapeutics employs 17 workers across the globe.

What is Soleno Therapeutics' official website?

The official website for Soleno Therapeutics is www.soleno.life.

Where are Soleno Therapeutics' headquarters?

Soleno Therapeutics is headquartered at 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065.

How can I contact Soleno Therapeutics?

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The company can be reached via phone at (650) 213-8444, via email at [email protected], or via fax at 650-213-8383.

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected]etbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.